[go: up one dir, main page]

TR201005326A2 - Multiple dosage forms. - Google Patents

Multiple dosage forms.

Info

Publication number
TR201005326A2
TR201005326A2 TR2010/05326A TR201005326A TR201005326A2 TR 201005326 A2 TR201005326 A2 TR 201005326A2 TR 2010/05326 A TR2010/05326 A TR 2010/05326A TR 201005326 A TR201005326 A TR 201005326A TR 201005326 A2 TR201005326 A2 TR 201005326A2
Authority
TR
Turkey
Prior art keywords
dosage forms
multiple dosage
hyperlipoproteinemia
hypertriglyceridemia
hypercholesterolemia
Prior art date
Application number
TR2010/05326A
Other languages
Turkish (tr)
Inventor
B�Lg�� Mahmut
Original Assignee
B�Lg�� Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B�Lg�� Mahmut filed Critical B�Lg�� Mahmut
Priority to TR2010/05326A priority Critical patent/TR201005326A2/en
Priority to PCT/TR2011/000164 priority patent/WO2012002921A1/en
Publication of TR201005326A2 publication Critical patent/TR201005326A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, hiperlipoproteinemi, hipertrigliseridemi, hiperkolesterolemi, miyokard enfarktüs ve strok ve/veya bunlarla ilişkili hastaiıklann tedavisinde kullanılmak üzere bir HMG-KoA reduktaz enzim inhibitörü ve bir fibrik asit türevini içeren farmasötik formülasyonlarla ilgilidir.The present invention relates to pharmaceutical formulations comprising an HMG-CoA reductase enzyme inhibitor and a fibric acid derivative for use in the treatment of hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, myocardial infarction and stroke and / or diseases associated with them.

TR2010/05326A 2010-06-30 2010-06-30 Multiple dosage forms. TR201005326A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2010/05326A TR201005326A2 (en) 2010-06-30 2010-06-30 Multiple dosage forms.
PCT/TR2011/000164 WO2012002921A1 (en) 2010-06-30 2011-06-29 Multiple dosage forms comprising fenofibrate or fenofibric acid in combination with hmg co a reductase inhibitors such as statins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/05326A TR201005326A2 (en) 2010-06-30 2010-06-30 Multiple dosage forms.

Publications (1)

Publication Number Publication Date
TR201005326A2 true TR201005326A2 (en) 2012-01-23

Family

ID=44513094

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/05326A TR201005326A2 (en) 2010-06-30 2010-06-30 Multiple dosage forms.

Country Status (2)

Country Link
TR (1) TR201005326A2 (en)
WO (1) WO2012002921A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102013028912A2 (en) * 2013-11-08 2017-02-14 Hypermarcas S A pharmaceutical composition, oral dosage form, capsule, double-layer tablet, uses, method of treating hypercholesterolemia, hypertriglyceridemia and / or mixed dyslipidemia, and method of preventing atherosclerosis, diabetes or secondary prevention of other cardiovascular diseases.
CN109369425B (en) * 2018-11-05 2022-01-04 陕西威信制药有限公司 Preparation method of fenofibric acid choline salt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
SI20109A (en) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
WO2005013940A1 (en) * 2003-08-06 2005-02-17 Galephar M/F Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
JP2007508249A (en) 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ Solid dosage form containing fibrates and statins
WO2006037345A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibrate and simvastatin
CA2597492A1 (en) 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor

Also Published As

Publication number Publication date
WO2012002921A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
BR112013011868A2 (en) hydroxy amide pyrimidine compounds as protein deacetylase inhibitors, pharmaceutical composition and use of said compounds
BRPI0917017B8 (en) s-nitrosoglutathione reductase pyrrole inhibitors as therapeutic agents
EA201171293A1 (en) 3-AZABICYCLO [4.1.0] HEPTANS APPLIED AS ANTAGONISTS OF OREXIN
CL2015000829A1 (en) Histone Demethylase Inhibitors
JO3366B1 (en) Pyrazolyl quinoxaline kinase inhibitors
BR112012019529A2 (en) d-nitrosoglutathione reductase inhibitors
MX385616B (en) CDK INHIBITORS
BR112012007747A2 (en) HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES
EA201591004A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201200551A1 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSED FORM, METHODS OF THEIR PRODUCTION AND APPLICATION FOR TREATMENT
JO3450B1 (en) New modified release dosage forms of xanthine oxidoreductase inhibitors or xanthine oxidase inhibitors.
CL2012002489A1 (en) Compounds derived from silyl naphtho-imidazole; pharmaceutical composition; and its use to prevent or treat a hepatitis c virus infection.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
MX377553B (en) STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USE THEREOF.
MY170935A (en) Neprilysin inhibitors
MD4556B1 (en) Compounds inhibiting the activity of catechol O-methyltransferase
EP2596122A4 (en) Modulators for sirt5 and assays for screening same
BR112014004310A2 (en) phosphodiesterase 10 enzyme inhibitor pyrimidine compound, pharmaceutical composition, use of a compound
TR201009397A2 (en) Pharmaceutical compositions containing rosuvastatin.
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
UY34314A (en) DERIVATIVES OF ANILINA, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION.
UA115052C2 (en) CONDENSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK- AND FAK INHIBITOR
BRPI0907486A2 (en) Triazolpyridazines as par1 inhibitors, their production and use as medicines
TN2016000207A1 (en) Pharmaceutical dosage forms.
TR201005326A2 (en) Multiple dosage forms.